Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; MEKINIST for cardiology; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; Reproxalap for opthamology; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida.…
Ligand Pharmaceuticals Sees Strong Royalty Growth Ahead of Investor Day, Oppenheimer Says
Ligand Pharmaceuticals (NASDAQ: LGND) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 47 employees.
The shares were at 286.85 USD on 20 November 2026, up 41.7% over 52 weeks. Its 52-week range is 175.89 USD to 325.86 USD: the price is 12.0% below the high and 63.1% above the low.
At a market capitalisation of 5.74B USD, it trades at 115.2 times trailing earnings and 24.0 times forward earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.1, a premium of 248% for LGND.
Ligand Pharmaceuticals reports return on equity of 12.2%, an operating margin of 14.4% and revenue down 31.8% year over year.
Its debt exceeds its cash by 706.81M USD, a debt-to-equity ratio of 0.44. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 11 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 361.27 USD is 25.9% above the current price. The next earnings report is expected on 25 February 2027.